EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
Conditions
Brief summary
Rate of IRRs occurring on Cycle 1 Day 1 following administration of oral lazertinib and IV amivantamab combination therapy, which is defined as IRR events with onset time within 24 hours of the start of the first amivantamab infusion and prior to the start of amivantamab infusion on Cycle 1 Day 2.
Interventions
Sponsors
Janssen - Cilag International
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of IRRs occurring on Cycle 1 Day 1 following administration of oral lazertinib and IV amivantamab combination therapy, which is defined as IRR events with onset time within 24 hours of the start of the first amivantamab infusion and prior to the start of amivantamab infusion on Cycle 1 Day 2. | — |
Countries
France, Spain
Outcome results
None listed